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etabolic Syndrome: Connecting and
econciling Cardiovascular and Diabetes Worlds
cott M. Grundy, MD, PHD
allas, Texas
The metabolic syndrome is a constellation of risk factors of metabolic origin that are
accompanied by increased risk for cardiovascular disease and type 2 diabetes. These risk
factors are atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, a
prothrombotic state, and a proinflammatory state. The two major underlying risk factors for
the metabolic syndrome are obesity and insulin resistance; exacerbating factors are physical
inactivity, advancing age, and endocrine and genetic factors. The condition is progressive,
beginning with borderline risk factors that eventually progress to categorical risk factors. In
many patients, the metabolic syndrome culminates in type 2 diabetes, which further increases
risk for cardiovascular disease. Primary treatment of the metabolic syndrome is lifestyle
therapy—weight loss, increased physical activity, and anti-atherogenic diet. But as the
condition progresses, drug therapies directed toward the individual risk factors might be
required. Ultimately, it might be possible to develop drugs that will simultaneously modify all
of the risk factors. At present such drugs are in development but so far have not reached the
level of clinical practice. (J Am Coll Cardiol 2006;47:1093–100) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.046College of Cardiology Foundation
t
e
n
fi
i
a
t
k
t
a
i
s
h
e
e
i
b
t
t
E
M
O
t
s
d
c
f
an 2001, the National Cholesterol Education Program
NCEP) Adult Treatment Panel III (ATP III) introduced
he metabolic syndrome as a risk partner to elevated
ow-density lipoprotein (LDL)-cholesterol in cholesterol
uidelines (1,2). This step was in response to the increasing
revalence of obesity and its metabolic complications in the
.S. The term metabolic syndrome was applied to the
lustering of risk factors that often accompany obesity and
ssociate with increased risk for both atherosclerotic cardio-
ascular disease (ASCVD) and type 2 diabetes. One advan-
age of identifying this particular cluster of risk factors is
hat it should bring together the fields of cardiovascular
isease and diabetes for a concerted and unified effort to
educe risk for both conditions simultaneously. Moreover,
ardiovascular disease is the foremost killer of patients with
iabetes, which is of interest to both fields (3).
ISK FACTOR CLUSTERING AND
ATHOGENESIS OF THE METABOLIC SYNDROME
he risk factors of the metabolic syndrome are of metabolic
rigin and consist of atherogenic dyslipidemia, elevated
lood pressure, elevated plasma glucose, a prothrombotic
tate, and a proinflammatory state (1,2,4–6). Atherogenic
yslipidemia comprises elevations of lipoproteins containing
polipoprotein B, elevated triglycerides, increased small
articles of LDL, and low levels of high-density lipopro-
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005, accepted November 1, 2005.eins (HDL). Elevated plasma glucose falls in the range of
ither pre-diabetes or diabetes. A prothrombotic state sig-
ifies anomalies in procoagulant factors (i.e., increases in
brinogen and factor VII), anti-fibrinolytic factors (i.e.,
ncreases in plasminogen activator inhibitor-1), platelet
berrations, and endothelial dysfunction. A proinflamma-
ory state is characterized by elevations of circulating cyto-
ines and acute phase reactants (e.g., C-reactive protein).
The pathogenesis of the metabolic syndrome is multifac-
orial (1,2,4–6). The major underlying risk factorsare obesity
nd insulin resistance. Risk associated with obesity is best
dentified by increased waist circumference (abdominal obe-
ity). Insulin resistance can be secondary to obesity but can
ave genetic components as well. Several factors further
xacerbate the syndrome: physical inactivity, advancing age,
ndocrine dysfunction, and genetic aberrations affecting
ndividual risk factors. The increasing prevalence of meta-
olic syndrome in the U.S. and worldwide, however, seems
o be driven largely by more obesity exacerbated by seden-
ary lifestyles (7).
VOLUTION OF THE
ETABOLIC SYNDROME CONCEPT AND THE NAME
ur understanding of the metabolic syndrome stems from
wo types of research. Epidemiological studies establish
trong association of obesity with ASCVD (8,9) and type 2
iabetes (10). Some of the increased risk for cardiovas-
ular disease is due to well-established, obesity induced risk
actors, (i.e., plasma cholesterol, elevated blood pressure,
nd diabetes) (11). These risk factors have been called the
etabolic complications of obesity (12,13). Cardiovascular
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Metabolic Syndrome CVD and Diabetes March 21, 2006:1093–100pidemiologists generally have not referred to this clustering
s a syndrome.
The naming of risk factor grouping as syndrome came
argely from the diabetes field. For example, Reaven (14,15)
oined the term “syndrome X” to signify a constellation of
etabolic risk factors associated with insulin resistance.
eaven (14,15) contends that insulin resistance is the
ominant underlying risk factor for syndrome X. In accord,
thers in the diabetes field have applied the name insulin
esistance syndrome (16–19). They have largely viewed obe-
ity as an exacerbating factor but without the same patho-
hysiological significance of insulin resistance. Among dia-
etologists, some have used the term metabolic syndrome as a
ore generic name for the aggregation of metabolic risk
actors (20–22). Regardless of the prefix, the diabetes field
eserves much of the credit for introducing the term
yndrome to define a grouping of metabolic risk factors. The
TP III guidelines (1,2) followed suit and employed the
ame metabolic syndrome because it seemed to be widely used
o describe risk-factor aggregation.
LINICAL OUTCOMES OF
HE METABOLIC SYNDROME:
ARDIOVASCULAR DISEASE AND TYPE 2 DIABETES
n patients with the metabolic syndrome, relative risk for
SCVD ranges form 1.5 to 3.0 depending on the stage of
rogression (23–34). When diabetes is not yet present, risk
or progression to type 2 diabetes averages about five-fold
ncrease compared with those without the syndrome (35–
9). Once diabetes develops, cardiovascular risk increases
ven more (40,41). The natural history of the metabolic
yndrome and its complications are described in Figure 1.
ost individuals who develop the syndrome first acquire
bdominal obesity without risk factors, but with time,
ultiple risk factors begin to appear. At the beginning, they
sually are only borderline elevated; later and in many
ndividuals they become categorically raised (42). In some,
he syndrome culminates in type 2 diabetes. If ASCVD
evelops, cardiovascular complications—cardiac arrhyth-
ias, heart failure, and thrombotic episodes—often ensue.
hose with diabetes can further acquire a host of compli-
ations including renal failure, diabetic cardiomyopathy, and
Abbreviations and Acronyms
ASCVD  atherosclerotic cardiovascular disease
ATP III  Adult Treatment Panel III
CB1  cannabinoid receptor-1
HDL  high-density lipoprotein
IDF  International Diabetes Federation
LDL  low-density lipoprotein
NCEP  National Cholesterol Education Program
PPAR  peroxisome proliferator-activated receptor
TZD  thiazolidinedione
WHO  World Health Organizationarious neuropathies. When ASCVD and diabetes exist
d
eoncomitantly, risk for subsequent cardiovascular morbidity
s very high. Patients with metabolic syndrome can manifest
variety of other conditions that complicate their manage-
ent: fatty liver, cholesterol gallstones, gout, and sleep
pnea. The presence of several or all of these outcomes
ommonly leads to the use of multiple medications (poly-
harmacy). No only does polypharmacy carry the risk of
dverse drug interactions but it interferes with compliance,
nd for many patients, imposes a prohibitive cost burden.
HE CONUNDRUM OVER CLINICAL
IAGNOSIS OF THE METABOLIC SYNDROME
n 1998, a diabetes working group of the World Health
rganization (WHO) proposed a set of criteria for a clinical
iagnosis of the metabolic syndrome (20). These included
linical evidence of insulin resistance, such as impaired
lucose tolerance, impaired fasting glucose, or type 2 dia-
etes, as necessary for the diagnosis. Two other risk factors
ere also needed: elevated triglycerides or low HDL, elevated
lood pressure, obesity, or microalbuminuria. Shortly after-
ard, the European Group for Study of Insulin Resistance
EGIR) proposed similar criteria for the insulin resistance
yndrome (18).
The ATP III (1,2) simplified the WHO criteria (18) by
equiring three of five simple clinical measures: increased
aist circumference (abdominal obesity), elevated triglycer-
des, reduced HDL cholesterol, elevated blood pressure, and
levated glucose. Abdominal obesity was not made a re-
uirement because some persons with insulin resistance can
ave multiple metabolic abnormalities without overt ab-
ominal obesity. The American Heart Association and
ational Heart, Lung, and Blood Institute recently reaf-
rmed the utility of ATP III criteria, with minor modifi-
ations (4,5) (Table 1). Simultaneously the International
iabetes Federation (IDF) (43) replaced WHO criteria
ith those closer to ATP III. Waist circumference thresh-
igure 1. Progression and outcomes of the metabolic syndrome. The
etabolic syndrome arises largely out of abdominal obesity. With aging
nd increasing obesity, metabolic risk factors worsen. Many persons with
he metabolic syndrome eventually develop type 2 diabetes. As the
yndrome advances, risk for cardiovascular disease and its complications
ncrease. Once diabetes develops, diabetic complications other than car-
iovascular disease often develop. The metabolic syndrome encompasses
ach stage in the development of risk factors and type 2 diabetes.
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March 21, 2006:1093–100 Metabolic Syndrome CVD and Diabeteslds were made ethnic-specific, and abdominal obesity was
equired for diagnosis. The latter simplifies diagnosis in
eveloping countries to save resources; only individuals
xceeding waist thresholds will require laboratory measure-
ents to finalize the diagnosis. Thus at last, the ATP III
pdate (4,5) and the IDF report (6) largely harmonize the
linical diagnosis of the syndrome.
SCVD RISK IN METABOLIC
YNDROME IS GREATER THAN THE
UM OF ITS MEASURED RISK FACTORS
he question has been raised as to whether the risk for
SCVD associated with the metabolic syndrome is greater
han the sum of its risk factors (44). The answer is the
ffirmative. First, epidemiological studies strongly suggest
hat multiple risk factors raise risk more than the sum of
ccompanying single risk factors (45–48); risk rises geomet-
ically instead of linearly. This phenomenon is called mul-
iplicative risk. Second, several metabolic risk factors are not
ncluded in standard risk algorithms; but all of them
eemingly impart independent risk for cardiovascular events.
hese are a prothrombotic state (49–51), a proinflamma-
ory state (52,53), and elevated triglyceride (54,55). This
dditional risk exceeds that which can be explained by
able 1. Diagnostic Criteria for Metabolic Syndrome
Measure (Any 3 of the 5
Criteria Below Constitute
a Diagnosis of Metabolic
Syndrome) Categorical Cut Points
levated waist
circumference*†
102 cm (40 inches) in men
88 cm (35 inches) in women
levated triglycerides 150 mg/dl (1.7 mmol/l)
or
drug treatment for elevated triglycerides‡
educed HDL-C 40 mg/dl (0.9 mmol/l) in men
50 mg/dl (1.1 mmol/l) in women
or
drug treatment for reduced HDL-C‡
levated blood pressure 130 mm Hg systolic blood pressure
or
85 mm Hg diastolic blood pressure
or
drug treatment for hypertension
levated fasting glucose 100 mg/dl
or
drug treatment for elevated glucose
To measure waist circumference, locate top of right iliac crest. Place a measuring tape
n a horizontal plane around abdomen at level of iliac crest. Before reading tape
easure, ensure that tape is snug but does not compress the skin and is parallel to
oor. Measurement is made at the end of a normal expiration. †In the U.S., some
dults of non-Asian origin (e.g., white, black, Hispanic) with a marginally increased
aist circumference (e.g., 94 to 101 cm [37 to 39 inches] in men and 80 to 87 cm [31
o 34 inches] in women) might have a strong genetic contribution to insulin
esistance; they should benefit from changes in life habits, similarly to men with
ategorical increases in waist circumference. A lower waist circumference cut point
e.g., 90 cm [35 inches] in men and 80 cm [31 inches] in women) appears to be
ppropriate for persons of Asian origin. ‡The most commonly used drugs for elevated
riglycerides (TG) and reduced high-density lipoprotein cholesterol (HDL-C) are
brates and nicotinic acid. A patient receiving one of these drugs can be presumed to
ave high TG and low HDL.tandard risk factors. Third, some of the risk attributed to
p
sstablished risk factors (e.g., hypertension and low HDL)
robably can be accounted for by unmeasured risk factors.
or example, blood pressure-lowering with drugs fails to
educe risk as much as predicted from epidemiological
tudies (56); a portion of the epidemiological risk attributed
o hypertension likely is subsumed by unmeasured risk
actors. Likewise, the robustness of low HDL to predict
SCVD risk almost certainly is due in part to the fact that
t is a marker for other metabolic risk factors (57,58).
nd fourth, because metabolic syndrome often progresses
nd culminates in type 2 diabetes, the syndrome’s long-
erm risk is underestimated at any one time. Thus several
ines of evidence indicate that the risk accompanying the
etabolic syndrome is greater than the sum of its
easured components.
IABETOLOGIST DISCONTENT
ITH NAMING OF THE METABOLIC SYNDROME
he cardiovascular community generally has embraced the
oncept of risk-factor clustering as a syndrome, even though
t originated in the diabetes field. Moreover, cardiovascular
nvestigators have been enthusiastic about the metabolic
yndrome because it accords well with the multiple-risk-
actor paradigm that is widely adopted for risk management.
onversely, the name metabolic syndrome poses problems for
ome investigators in diabetes. The reasons can be summa-
ized briefly (Fig. 2).
First, a group of researchers believes that insulin resis-
ance is the dominant cause of the syndrome (14–19,59).
hese investigators prefer the term insulin resistance syn-
igure 2. Interrelations and overlap of metabolic syndrome with insulin
esistance, prediabetes, and type 2 diabetes. According to the insulin
esistance hypothesis, the metabolic syndrome is caused predominantly by
nsulin resistance. The latter also contributes to prediabetes and, ultimately,
o type 2 diabetes. About 75% of people with prediabetes and 86% of
eople with type 2 diabetes have the metabolic syndrome. Both metabolic
yndrome and type 2 diabetes are known to predict cardiovascular disease.
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Metabolic Syndrome CVD and Diabetes March 21, 2006:1093–100rome. The name metabolic syndrome leaves open a multifac-
orial causation, countering one view of the essential patho-
enesis. According to the insulin-resistance hypothesis,
ven obesity elicits the metabolic risk factors through insulin
esistance.
Second, the term prediabetes, which encompasses im-
aired fasting glucose and impaired glucose tolerance, is
eant to identify an elevated risk for type 2 diabetes (60).
et approximately 70% to 75% of individuals with predia-
etes meet clinical criteria for the metabolic syndrome
61,62). According to some investigators (63–65), predia-
etes carries a predictive power for ASCVD similar to that
f metabolic syndrome (63–65). But this predictive poten-
ial most likely can be explained by accompanying metabolic
isk factors (66). Consequently, the overlap between predi-
betes and metabolic syndrome creates a tension for nomen-
lature within the diabetes world.
Third, both ATP III and IDF criteria (4–6) allow for a
iagnosis of metabolic syndrome to be applied to patients
ith type 2 diabetes who manifest a clustering of risk
actors characteristic of the syndrome. The ATP III
ndeed defines diabetes itself as a high-risk condition for
SCVD. This high risk is due largely to associated risk
actors. For example, Alexander et al. (29) reported that the
etabolic syndrome, as defined by ATP III, accounts for
ost of the increased risk for congenital heart disease
ccompanying type 2 diabetes. Moreover, about 86% of
ersons over age 50 years living in the U.S. and who have
ype 2 diabetes will qualify for a diagnosis of metabolic
yndrome (29). Therefore, it is not surprising that the
verlap between metabolic syndrome with categorical hy-
erglycemia and type 2 diabetes poses significant identity
ssues for the diabetes community. It is not entirely clear
hether type 2 diabetes as a concept is strictly hyperglyce-
ia caused by concomitant insulin resistance and decreased
nsulin secretion (67,68) or whether it should include the
etabolic syndrome as one of its components (29).
Regarding type 2 diabetes, the conflict in nomenclature
nd definitions has important clinical implications. Cardio-
ascular risk factors in most patients with type 2 diabetes
eserve greater clinical attention than they currently receive.
ntensive management including drug treatment usually is
equired for elevated cholesterol and blood pressure, not to
ention hyperglycemia; furthermore, low-dose aspirin typ-
cally is recommended for most patients with type 2 diabetes
o reduce a prothrombotic state (69). Unfortunately, many
hysicians who treat patients with type 2 diabetes have
ailed to recognize the necessity to substantially lower
holesterol and blood-pressure levels and to add aspirin
rophylaxis. Clinical trials clearly document benefit of
ntensive reduction of non-glucose risk factors—cholesterol
70–73) and blood pressure (74,75)—in patients with type
diabetes. This need is strongly stated in cholesterol and
lood pressure guidelines (1,2,75). For this reason, it be-
ooves diabetes agencies as well as the cardiovascular field to
ake an aggressive approach to management of all cardio- aascular risk factors in patients with type 2 diabetes who
ave features of the metabolic syndrome.
HE METABOLIC SYNDROME IS NOT A RELIABLE
ISK ASSESSMENT TOOL FOR SHORT-TERM RISK
he metabolic syndrome carries increased long-term risk
oth for ASCVD and diabetes as well as higher short-term
isk. The ATP III (1,2) introduced the syndrome primarily
o augment the clinical management of obese persons who
ave progressed to the stage of multiple risk factors (Fig. 1).
mportantly, the metabolic syndrome is not a reliable tool
or global risk assessment for ASCVD in the short term
e.g., 10-year risk). It does not include all of the risk factors
ontained in standard risk-prediction algorithms (e.g., age,
ender, total cholesterol, smoking status). Thus, 10-year
isk assessment is best carried out with algorithms such as
ramingham risk scoring (1,2). Even so individuals with the
etabolic syndrome live on a higher trajectory of long-term
isk for both ASCVD and type 2 diabetes. Consequently,
he progressive nature of the syndrome should be recognized
Fig. 1).
But even risk algorithms based on established risk factors
re limited in predictive power for individuals. More effec-
ive prediction tools are needed. One promising technique is
dentification of atherosclerotic burden through non-
nvasive imaging (76,77). The finding of significant athero-
clerotic burden in patients who otherwise would not be
dentified as being at high risk could trigger more intensive
nterventions such as cholesterol-lowering drugs and low-
ose aspirin. Patients with the metabolic syndrome might
e particularly good candidates for atherosclerosis imaging.
o date, however, the potential of this strategy has not been
ully developed.
All patients with the metabolic syndrome deserve global
isk assessment, whether by risk-factor algorithms or by
therosclerosis imaging; its essential purpose is to identify
andidates for drug therapies for prevention. But once a
erson is found to have the syndrome, lifestyle therapies
hould be introduced, reinforced, and monitored. Drug
herapy is a secondary consideration that should be guided
y global risk assessment.
IFESTYLE MODIFICATION IS THE
RIMARY THERAPY OF THE METABOLIC SYNDROME
he ATP III (1,2) embedded the metabolic syndrome into
holesterol guidelines to reinforce clinical lifestyle therapies.
hese therapies consist of weight reduction, increased
hysical activity, and an anti-atherogenic diet; smoking
essation in addition is mandatory. Lifestyle intervention
nfortunately is often neglected in routine practice. It has
he potential to reduce the severity of all metabolic risk
actors at every stage of progression as well as to slow their
rogression (8) (Fig. 1). Drug therapies of established risk
actors alone are not sufficient to completely reverse risk
ssociated with the syndrome (i.e., risk for either ASCVD
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March 21, 2006:1093–100 Metabolic Syndrome CVD and Diabetesr diabetes). Clinical trials consistently show a substantial
esidue of risk that cannot be reversed with drugs (56,72).
ifestyle modifications are one way to cut into this residual
isk. In addition, institution of lifestyle therapies early in the
yndrome can delay risk-factor progress and the need for
rug therapies. Beyond reducing risk for cardiovascular
isease, weight reduction and increased physical activity
lows progression to type 2 diabetes in individuals with the
etabolic syndrome (78,79). Thus the combined effect of
ifestyle therapies to reduce cardiovascular risk factors and
mergence of diabetes doubly validates the primacy of
ifestyle intervention for this syndrome.
AS THE PHARMACEUTICAL INDUSTRY
SURPED THE METABOLIC SYNDROME?
hen ATP III guidelines were crafted to include the
etabolic syndrome, the pharmaceutical industry recog-
ized it as a potential target of drug therapy. The idea of
educing multiple risk factors with a single drug or a drug
ombination obviously is attractive and needed. It is curious
hat one criticism leveled against the metabolic-syndrome
oncept is that the pharmaceutical industry has tried to take
dvantage of it to promote or develop new drugs. New drug
evelopment need not detract from the priority given to
ifestyle modification. Moreover, the challenge for develop-
ng a new drug that will substantially reduce multiple risk
actors is formidable. Some in industry might have hoped
hat the scientific community would agree on a single criterion
or the syndrome and, if so, that regulatory agencies would
ccept this criterion so that a new drug could be registered for
he metabolic syndrome. This hope is unrealistic, not because
f the lack of a single criterion, but because regulatory agencies
re unlikely to allow registration for new targets in the
ardiovascular field without clinical end-point trials.
At present, the only drugs approved for treatment of risk
actors are those that target the individual risk factors:
ipid-lowering drugs, antihypertensive agents, hypoglycemic
rugs, anti-platelet drugs, and weight-loss agents. For the
se of these drugs in persons with the metabolic syndrome,
physician should follow current treatment guidelines of
he NCEP (1,2), the Sixth Joint National Commission for
lood pressure treatment (75), the American Diabetes
ssociation (69,80), the American Heart Association/
merican College of Cardiology (81,82), and the National
nstitutes of Health Obesity Initiative (8). Pharmacological
herapies for the two underlying risk factors for the
yndrome—obesity and insulin resistance—are under devel-
pment, albeit in the early stages. They nonetheless hold
romise for adding benefit for delaying progression of the
ondition. Candidate drugs for treatment of the metabolic
yndrome as a whole and to reduce risk for ASCVD and/or
iabetes are weight-reduction drugs, peroxisome proliferator-
ctivated receptor (PPAR)-alpha agonists (fibrates), PPAR-
amma agonists (thiazolidinediones [TZDs]), and dual PPAR
gonists. mTwo weight-loss drugs—sibutramine and orlistat—are
lready approved by the Food and Drug Administration.
hese improve all of the metabolic syndrome risk factors
ut produce only a moderate weight loss (83,84). A new and
romising weight-loss drug is a selective cannabinoid
eceptor-1 (CB1) antagonist called rimonabant. Endocan-
abinoids, which activate G-protein–coupled CB1 in hypo-
halamus and limbic forebrain, accentuate hyperphagia (85).
imonabant suppresses endogenous activation of the endo-
annabinoid system (86). The drug causes a 5% to 10%
eight loss up to two years (87) and might have systemic
ctions that independently reduce risk factors for the met-
bolic syndrome (88,89).
Clinical trials suggest that fibrates will independently
educe risk for ASCVD through treatment of atherogenic
yslipidemia, possibly because of their anti-inflammatory
roperties (2). The TZDs lessen insulin resistance and
odestly improve the various metabolic risk factors. A
ecent clinical trial found a strong trend toward decreasing
ardiovascular outcomes with one TZD, pioglitazone (90).
ual PPAR agonists combine PPAR-alpha and PPAR-
amma agonism in a single agent and thus have favorable
ffects on several metabolic risk factors (91,92). In spite of
romise, all of these drugs have outcome hurdles to mount
efore they can be approved for routine use in patients with
he metabolic syndrome.
ONCLUSIONS
he metabolic syndrome consists of a clustering of risk
actors of metabolic origin that together are associated with
igher risk for ASCVD and diabetes. The syndrome occurs
n approximately one-fourth of American adults. It is
ccompanied by insulin resistance but its increasing preva-
ence is due largely to escalating obesity. Simple clinical
riteria are available to identify persons most likely to have
he syndrome. These individuals typically have several
etabolic risk factors that are not measured in clinical
ractice; thus the syndrome as a whole conveys a greater risk
or ASCVD and diabetes than revealed by usual clinical
easures. Moreover, the syndrome is a progressive condi-
ion that worsens with advancing age and increasing obesity.
t often culminates in type 2 diabetes, which carries a
articularly high risk for both cardiovascular events and
ther complications. The metabolic syndrome itself is not a
obust risk assessment tool for estimating absolute 10-year
isk; but its presence calls for more extensive short-term risk
ssessment, either by risk-factor scoring or imaging for
ubclinical atherosclerosis. The primary intervention is life-
tyle therapy, particularly weight reduction and increased
xercise. Lifestyle therapies will dampen the syndrome and
low its progression at every stage but particularly in its early
hases. Drug therapies should be based on global risk
ssessment and should follow current treatment guidelines
or each of the risk factors. But new drugs under develop-
ent promise to better treat the syndrome as a whole. The
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Metabolic Syndrome CVD and Diabetes March 21, 2006:1093–100etabolic syndrome should serve to bring cardiovascular
nd diabetes fields together in a joint effort to reduce both
SCVD and diabetes. At present this joint action is being
ampered by the issue of how to integrate the metabolic
yndrome into concepts of insulin resistance, prediabetes,
nd type 2 diabetes, all of which are important to the
iabetes field. Nonetheless, the common clustering of met-
bolic risk factors in obese persons is a fact of American
edicine; and it deserves increased attention for clinical
anagement of affected patients.
eprint requests and correspondence: Dr. Scott M. Grundy,
niversity of Texas Southwestern Medical Center at Dallas, 5323
arry Hines Boulevard, Y3.206, Dallas, Texas 75390-9052.
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